As of August 13, 2026, retatrutide is neither approved nor available on prescription in France. Trials include French sites, and a US program now allows some individual access before approval. Neither arrangement turns the pens and vials sold online into legal or quality-controlled medicines.
The signal is strong enough to attract attention, but not to justify self-injection. The human results are substantial. So are the regulatory and safety unknowns.
What is retatrutide?
Retatrutide, also known as LY3437943, is an experimental molecule developed by Lilly. It activates three hormone receptors: GLP-1, GIP and glucagon receptors. The nickname “GLP-3” seen online is misleading, as it does not refer to any recognized scientific class.
GLP-1 and GIP help regulate blood glucose and food intake, among other functions. Activating the glucagon receptor adds effects on the mobilization of energy substrates. This combination offers a coherent pharmacological rationale for treating obesity and diabetes. It is not enough to demonstrate a clinical benefit, which is why the molecule is undergoing comparative trials.
Retatrutide is not a dietary supplement or an upgraded version of a medicine you could swap out yourself. To compare its experimental efficacy with tirzepatide without confusing their regulatory status, see our retatrutide versus tirzepatide analysis · FR.
Is it approved or available in France?
The regulatory answer is no. Lilly states that retatrutide has not been approved by any agency. The European Union medicines register, updated on August 12, 2026, contains no authorization under that name. The ANSM lists it among peptides offered without authorization.
Three situations must be kept separate:
| Situation | What it allows | What it does not allow |
|---|---|---|
| Clinical trial | receiving a research intervention under a protocol, after selection and consent | freely choosing the product, avoiding a possible placebo or obtaining a routine prescription |
| US expanded access | treating an individual patient who meets stringent criteria, at their physician’s request | selling the product to the public, proving its efficacy or creating a right of access in France |
| Prescription in France | dispensing an authorized medicine through the pharmaceutical supply chain | routinely prescribing retatrutide while it has no authorization |
The new US expanded access program covers adults with severe, treatment-resistant obesity and at least two serious complications who cannot participate in a trial. The request comes from the physician, and access depends on factors including individual assessment, geographical area and supplies. The FDA notes that compassionate access specifically concerns a product it has not yet deemed safe and effective for the requested use.
Where do clinical trials stand?
Development has moved beyond proof of concept. Several phase 3 trials have been completed, while studies of cardiovascular, kidney and liver events continue.
Here is the relevant timeline as of August 13, 2026:
| Date | Verified milestone | What to take from it |
|---|---|---|
| 2021 to 2022 | phase 2 obesity trial, 338 adults | first controlled evidence of efficacy and tolerability |
| June 2023 | peer-reviewed publication in the NEJM | promising results, but duration limited to 48 weeks |
| 2023 to 2026 | TRIUMPH and TRANSCEND phase 3 program | confirmation across several populations and complications |
| June 2026 | publication in the Lancet of a phase 3 trial in type 2 diabetes | first major phase 3 publication, funded by Lilly |
| July 23, 2026 | preliminary TRIUMPH-2 and TRIUMPH-3 results announced by Lilly | positive sponsor-reported data, detailed publication still awaited |
| Q1 2027 | US filing announced by Lilly | projected timeline, not an approval date |
French sites, but no general access
The ClinicalTrials.gov registry lists 16 French sites in TRIUMPH-Outcomes. This study of 10,000 participants is tracking cardiovascular and kidney events through 2029, but its status is “active, not recruiting”: it is continuing without enrolling new participants.
SYNERGY-Outcomes, a phase 3 protocol for high-risk metabolic dysfunction-associated steatotic liver disease, includes retatrutide among several interventions. The registry lists 17 French sites, including 14 recruiting as of August 13. Eligibility depends on a specific liver disease, not simply a wish to lose weight. Each site’s status can change.
Observed results and remaining uncertainties
In the phase 2 trial published in 2023, average weight reduction reached 24.2% at 48 weeks in the highest-exposure group, compared with 2.1% with placebo. This figure is an average among adults with obesity, or overweight with at least one weight-related complication. It is neither an individual promise nor proof that the loss is maintained after stopping.
The TRANSCEND-T2D-1 trial, published in 2026, randomized 537 adults whose type 2 diabetes remained inadequately controlled through diet and physical activity. At 40 weeks, average weight reduction reached up to 15.3% in the highest-exposure group, compared with 2.6% on placebo. HbA1c also fell more. This population with diabetes and this duration do not answer every question about obesity without diabetes.
In July 2026, Lilly announced average weight reductions of up to 20.8% in TRIUMPH-2 and 22.6% in TRIUMPH-3 at 80 weeks. These results come from a sponsor press release. Detailed data and their peer-reviewed publication are still awaited.
The unknowns that still prevent it from being considered an established treatment are concrete: long-term maintenance, regain after stopping, rare events, safety in underrepresented populations and clinical cardiovascular or kidney effects. TRIUMPH-Outcomes is not expected before 2029.
Adverse effects and monitoring
In published trials, the most common events are gastrointestinal: nausea, diarrhea, vomiting and constipation. In the phase 2 obesity trial, they increased with exposure and were most often mild to moderate. An exposure-dependent increase in heart rate peaked at 24 weeks before declining.
In TRANSCEND-T2D-1, discontinuations due to adverse effects affected 2–5% of the retatrutide groups, compared with none on placebo. No episodes of severe hypoglycemia were reported. The two deaths observed were judged unrelated to the product by the investigators. The trial was funded by Lilly, and several authors were company employees or shareholders—a conflict that should remain visible without automatically invalidating the results.
There is not yet an authorized European package leaflet defining indications, contraindications and routine monitoring. Copying the monitoring used for another agonist does not fill that gap. In a trial, selection, examinations and stopping rules are governed by the protocol and the medical team.
Why products sold online are particularly risky
The ANSM has received several reports following the use of fraudulent peptides, including retatrutide, involving hospitalizations. It cites gastrointestinal disorders, dehydration, feeling unwell, liver injury, injection-site infections and severe allergic reactions. The agency provides no denominator, so these reports cannot be used to calculate a frequency.
An Australian analysis published online on August 6, 2026, provides more direct chemical evidence. All three vials studied did contain retatrutide, but the measured quantity ranged from 51.3% to 190% of the stated amount. Three samples do not represent the entire market. Crucially, the study tested neither sterility nor endotoxins.
The label “research use only” closes none of these gaps. An injectable product requires separate checks of identity, content, impurities, sterility, endotoxins and stability. Our investigation into the risks of peptides sold online · FR explains why a purity certificate does not cover that chain.
Under French law, a product presented as treating obesity or causing weight loss may meet the definition of a medicine. In July 2026, the ANSM ordered the suspension and withdrawal of products presented as containing retatrutide because they lacked authorization and a compliant pharmaceutical supply chain. An available checkout page does not make the sale legal.
If you have already used a product obtained outside the regulated supply chain, follow the ANSM’s advice:
- stop using it
- promptly consult a healthcare professional if you experience an adverse effect
- call 15 or 18 in a life-threatening emergency
- report the event through the national reporting portal
How to track future official decisions
Do not rely on a launch date announced by a seller. Check these milestones instead:
- an application followed by a public EMA opinion
- an authorization decision entered in the European Union register
- an authorization and package leaflet in the French public medicines database
- changes in trial status in CTIS or ClinicalTrials.gov
- full phase 3 publications, distinct from financial press releases
The US filing projected for 2027 predicts neither the FDA’s decision, the European timeline nor availability in France. Until an authority publishes its decision, any precise date remains speculative.
The Le Biohacker verdict
Retatrutide is a serious drug candidate, not a ready-to-use biohacking product. Trials show substantial weight reductions and improved blood glucose control in defined populations. They do not justify bypassing authorization, pharmaceutical manufacturing and medical supervision.
My verdict is clear: in France, wait for an official decision or consider only a trial for which you are genuinely eligible. US compassionate access is not a prescription through the back door. A vial “for research use only” is not a shortcut to phase 3—it is an extra layer of risk.
